AllSci News
Seattle Children's Hospital picks up USD 2.1m NIH grant for AI nanobody engineering platform
An AI-driven approach to nanobody engineering is drawing federal support, with Seattle Children's Hospital receiving a USD 2.1 million NIH R01 grant to...
Allterum's anti-CD127 mAb 4A10 enters Phase I for relapsed/refractory acute lymphoblastic leukemia
Allterum Therapeutics is advancing 4A10, a fully human anti-CD127 IgG1 monoclonal antibody licensed from the National Cancer Institute, into a...
Relay Therapeutics' NRAS-selective inhibitor RLY-8161 enters Phase I for NRAS-mutant cancers
Relay Therapeutics launches first-in-human RLY-8161 clinical trial in NRAS-mutant cancers
Chipscreen puts PRMT5 inhibitor into Phase I for MTAP-deleted solid tumors and lymphoma
Chengdu Chipscreen Pharmaceuticals, a subsidiary of Shenzhen-based Chipscreen Biosciences (SSE: 688321), has registered a first-in-human clinical trial for...
Vertex Pharma expands neurology pipeline with first-in-human trial for small-molecule narcolepsy drug
Vertex Pharmaceuticals is advancing VX-433, an oral investigational compound, into a first-in-human Phase I clinical trial targeting narcolepsy type 1, a...
FDA approves expanded dosing regimen for Kyowa Kirin’s Crysvita in adult XLH
Japan’s Kyowa Kirin, Inc. (JPX: 4151.T) has received US FDA approval for an updated dosing regimen for Crysvita (burosumab-twza) in adults with…
Mirum Pharma issues USD 600m convertible notes to refinance 2029 debt, fund rare disease acquisitions
Foster City, California-based Mirum Pharmaceuticals (Nasdaq: MIRM) has announced the pricing of USD 600 million in aggregate principal of 0.00% convertible...
Gilead fills acquisitions war chest with USD 3b senior note offering
Gilead Sciences (Nasdaq: GILD) has announced the pricing of USD 3 billion in senior unsecured notes across four tranches in an underwritten registered...
Akeso's ligufalimab shows 80% response rate in Phase II treatment-naïve AML trial
Akeso (HKEX: 9926.HK) reported Phase II data from its ligufalimab AML trial showing an objective response rate of 80.0% versus 66.7% for placebo in...
Chengdu Origen and Vanotech receive FDA clearance for KHN921 gene therapy in hypertrophic cardiomyopathy
Chengdu Origen Biotechnology and Vanotech have received US FDA clearance to proceed with a Phase I/II clinical trial of KHN921, an AAV9-based gene therapy...
HCW Biologics' fusion immunotherapeutic prevents bronchopulmonary dysplasia in preclinical models
HCW Biologics reports HCW11-040 prevents bronchopulmonary dysplasia in IND-enabling animal studies
CapeHaven completes first close toward USD 10 million seed funding for Yale biotech spinouts
CapeHaven launches Yale biotech spinout vehicle with USD 10 million target
Biogen completes USD 3.2b acquisition of Apellis Pharma for complement inhibitor assets
Biogen (Nasdaq: BIIB) has completed its acquisition of Apellis Pharmaceuticals, adding two commercially approved complement inhibitors and an established...
Taiwan's Bora Pharma adds MacroGenics' GMP manufacturing for USD 127.5m
Taiwan-based Bora Pharmaceuticals (TWSE: 6472; OTCQX: BORAY) has agreed to acquire the GMP manufacturing operations of MacroGenics (Nasdaq: MGNX) for USD...
In vivo CAR-T funding continues to flow as Create Medicines raises USD 122m in Series B
CREATE Medicines raises USD 122 million Series B to advance in vivo CAR pipeline
The AllSci Brief
Free, systematic R&D and deal news. Daily.